Episode 59
Biotech Hangout
00:00
The EQRX Water Cooler and TGTX
This week, EQRX announced that as part of a business reset, the company is no longer pursuing a corporate strategy around competitive drug pricing. With that said, they have $1.3 billion in cash. And one also wonders whether what investors think and whether an activist could get involved in demand distribution of cash.
Transcript
Play full episode
